Study of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects With Peripheral Ischemic Ulcers
- Conditions
- Peripheral Artery DiseaseIschaemic Ulcer of Lower Leg Due to Atherosclerotic DiseaseChronic Limb Threatening IschemiaIschemic Ulcer of Foot
- Interventions
- Biological: PlaceboBiological: AMG0001
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- AnGes USA, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04267640
- Locations
- 🇺🇸
ILD Research Center, Carlsbad, California, United States
🇺🇸Oregon Health & Sciences University, Portland, Oregon, United States
🇺🇸Limb Preservation Platform, Inc., Fresno, California, United States
A Long Term Follow-up Study of AMG0001 in Subjects With Critical Limb Ischemia
- Conditions
- Critical Limb Ischemia
- Interventions
- Biological: Subjects from Study AG-CLI-0206 who received AMG0001
- First Posted Date
- 2016-11-28
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- AnGes USA, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT02974179
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Efficacy and Safety of AMG0001 in Subjects With Critical Limb Ischemia
- Conditions
- Critical Limb Ischemia
- Interventions
- Biological: Matching PlaceboBiological: HGF Plasmid (AMG0001)
- First Posted Date
- 2014-05-22
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- AnGes USA, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT02144610
- Locations
- 🇺🇸
Alliance Research Centers, Laguna Hills, California, United States
🇺🇸Mercy Medical Research Institute, Springfield, Missouri, United States
🇺🇸Emory University, Atlanta, Georgia, United States
A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia
- Conditions
- Peripheral Arterial DiseaseVascular DiseasesCritical Limb Ischemia
- Interventions
- Biological: HGF Plasmid
- First Posted Date
- 2013-12-20
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- AnGes USA, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02016755
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers
- Conditions
- Arterial Occlusive DiseasePeripheral Vascular DiseaseIschemiaUlcers
- Interventions
- Genetic: PlaceboGenetic: HGF plasmid
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- AnGes USA, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT00189540
- Locations
- 🇺🇸
The Care Group, LLC, Indianapolis, Indiana, United States
🇺🇸Baptist Clinical Research, Pensacola, Florida, United States
🇺🇸Dartmouth - Hitchcock Medical Center, Lebanon, New Hampshire, United States
Study of HGF Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia
- Conditions
- Arterial Occlusive DiseasePeripheral Vascular DiseaseIschemia
- Interventions
- Genetic: HGF plasmid
- First Posted Date
- 2003-05-16
- Last Posted Date
- 2008-01-11
- Lead Sponsor
- AnGes USA, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT00060892
- Locations
- 🇺🇸
The Ochsner Heart and Vascular Institute, Metairie, Louisiana, United States
🇺🇸University of South Florida College of Medicine, Tampa, Florida, United States
🇺🇸Cardiology, P.C., Birmingham, Alabama, United States